Common questions about Millis (FAQ)
Q: How quickly should I expect to feel the effects of Millis?
A: Official prescribing information indicates that the active ingredient in Millis is absorbed very quickly through the oral lining. Clinical studies show that the maximum concentration of the medication in the bloodstream is typically reached within 5 to 7.5 minutes following administration, leading to a rapid pharmacological effect.
Q: Can Millis be taken with other maintenance medications for chronic conditions?
A: Regulatory documents advise caution when Millis is used with any medication that lowers blood pressure, such as Beta-Blockers or Calcium Channel Blockers. This is due to the potential for additive effects, which could cause blood pressure to drop too low. Information about all other medicines should be reviewed by a healthcare provider.
Q: What should I do if the side effects from Millis feel too strong?
A: If you experience severe side effects like extreme dizziness, feeling faint, or lightheadedness, these may be signs of a dangerously low blood pressure drop. Official guidance recommends sitting or lying down immediately to help prevent fainting. If symptoms persist or are concerning, consult with a healthcare professional.
Q: How does Millis compare to older treatments for the same condition?
A: Clinical studies comparing the spray formulation to older sublingual tablets indicate that the spray generally provides a similar anti-anginal effect. Some data suggests that this formulation may be associated with a different side effect profile, including potentially fewer reports of headache.
Q: Is Millis safe for people with high blood pressure?
A: Millis is a vasodilator, which means it is designed to lower blood pressure. Therefore, caution is required when it is used by individuals with existing high blood pressure or those taking blood pressure medications. Official product information stresses the need to avoid use with certain other medications due to the risk of severe hypotension (very low blood pressure).
Q: How should Millis be stored (temperature, light, etc.)?
A: Regulatory requirements state that Millis must be stored at controlled room temperature and protected from heat and light. Because the product is a pressurized, flammable canister, it must never be frozen, punctured, or incinerated, and should be kept out of the sight and reach of children.
Q: What is the biggest difference between Millis and other similar medications?
A: The key distinction is the specific formulation as an oromucosal spray and the sublingual (under the tongue) route of administration. This delivery method is designed for very rapid absorption directly into the bloodstream. This provides a quick pharmacological effect, setting it apart from slower-acting nitrate medications or different formulations.
Q: Is a metallic taste in the mouth normal when starting Millis?
A: Official adverse reaction reports do not explicitly list a metallic taste as a common side effect. However, a small number of patients have reported general taste disturbances. These sensations, when reported, are often described as mild and temporary.
Q: Can taking Millis make you feel dizzy or lightheaded?
A: Yes, dizziness, vertigo, and lightheadedness are common side effects documented in the official product information. These effects are often related to the primary action of the drug, which involves lowering blood pressure. Patients are informed about these potential effects.
Q: How long does Millis typically stay in your system?
A: The half-life of the active ingredient, which is a measure of how quickly the drug is cleared, is reported to be very short, typically between 1 and 4 minutes. This rapid clearance is consistent with its use as a fast-acting, short-duration medication for acute events.
Q: Why do some people feel very tired after taking Millis?
A: Official labeling lists asthenia, a medical term referring to a lack of energy or weakness, as a common adverse reaction. This feeling of generalized weakness can be interpreted by users as tiredness after administration.
Q: Are there any mood changes that can happen while taking Millis?
A: While significant mood changes are not listed as common side effects, some reports have included mild psychiatric adverse reactions, such as feelings of restlessness or apprehension. This information comes from official safety surveillance reports.
Q: What were the major findings from the clinical trials for Millis?
A: Key findings from clinical trials established the spray’s rapid effectiveness. Studies demonstrated a statistically significant reduction in the time patients took to report relief compared to a placebo. Additionally, the medicine appeared to change the measured time participants could exercise before symptoms began during controlled exercise tests.
Q: Can Millis be crushed or split if it's a tablet?
A: Millis is not manufactured as a tablet or capsule. It is supplied as an oromucosal spray within a specialized canister. Therefore, there are no instructions provided for crushing or splitting the medication, as it is only intended for administration via spray onto or under the tongue.
Q: Can taking Millis affect my ability to drive or operate machinery?
A: Yes. Official safety information advises caution because side effects like dizziness, vertigo, and lightheadedness are common. These symptoms may impair your ability to safely drive or operate machinery, particularly when you first start treatment or after a dose is administered.
Q: Is there a maximum time someone can safely take Millis?
A: There is no fixed limit on the total duration of use for Millis. However, for continuous, long-term use of nitrate medications, official guidance recommends incorporating a daily nitrate-free interval, typically 10 to 12 hours, to help prevent pharmacological tolerance from developing.
Q: Can Millis cause temporary changes in vision?
A: Although it is not a common side effect, official adverse event reports have listed blurred vision as a rare adverse reaction. This suggests that some temporary visual changes may occur in a small number of users.
